Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (CYCN) is a Nasdaq-listed clinical-stage biopharmaceutical company that provides frequent updates on its progress in neuropsychiatric drug development and the monetization of its legacy soluble guanylate cyclase (sGC) portfolio. This news page aggregates company press releases and market-moving announcements so readers can follow how Cyclerion’s strategy and pipeline evolve over time.
Recent news highlights Cyclerion’s transformation into a neuropsychiatric company, centered on an individualized therapy for treatment-resistant depression (TRD). The company has reported a license agreement with the Massachusetts Institute of Technology for technology to treat neuropsychiatric disorders and has announced CYC-126, an anesthetic-based investigational therapy that uses real-time EEG monitoring and algorithm-guided dosing, as its lead program for TRD.
Investors and observers can also track Cyclerion’s collaboration and business development activity. Updates include an application-specific, exclusive collaboration with Medsteer SAS to integrate closed-loop anesthetic delivery technology into CYC-126, as well as agreements to sell or license legacy sGC assets such as zagociguat, CY3018, praliciguat, and olinciguat. These items illustrate how the company aims to generate non-dilutive funding while building its neuropsychiatric pipeline.
In addition, the news flow covers corporate governance and capital markets developments, including board appointments, leadership changes, reverse stock split actions, and Nasdaq listing compliance updates. By reviewing this page regularly, readers can follow Cyclerion’s clinical plans, partnership announcements, licensing milestones, and strategic updates that may influence the CYCN stock narrative.
Cyclerion Therapeutics (Nasdaq: CYCN) announced an upcoming webcast investor event on July 9, 2020, from 8:15 a.m. to 9:30 a.m. Eastern Time, focusing on IW-6463, a CNS-penetrant sGC stimulator for serious CNS diseases. The company has completed dosing in the IW-6463 clinical study, with topline data expected in late summer 2020. The webcast will cover the therapeutic potential of the nitric oxide/sGC system, preclinical and Phase 1 study data, and future directions for CNS therapies. The event will be available on the Cyclerion website and archived for 21 days.